FDA's oversight of drug postmarketing studies will get a boost from ongoing and planned informatics systems upgrades, a new HHS Office of the Inspector General report suggests. For sponsors, the biggest impact will likely be learning a new report submission format – and facing more scrutiny if a study falls behind schedule.
Efforts to build capacity in the agency's current drug application tracking system will make it easier to determine whether required...




